Details of the Drug Combinations

General Information of This Drug (ID: DMHTY9W)

Drug Name
Ublituximab   DMHTY9W
Synonyms TG-1101
Indication
Disease Entry ICD 11 Status REF
Multiple sclerosis 8A40 Approved [1]
Chronic lymphocytic leukaemia 2A82.0 Phase 3 [2]
Lymphoma 2A80-2A86 Phase 1/2 [3]
Nodal marginal zone lymphoma 2A85.0 Phase 1/2 [3]
Drug Type
Antibody

List of Combinatorial Drugs (CBD) Containing This Drug

1 Clinical Trial Drug Combination(s) Consisting of This drug
DrugCom Name DrugCom ID Component Drug Indication REF
Ublituximab + Umbralisib DC3W3HZ Umbralisib Chronic lymphocytic leukaemia; Non-hodgkin lymphoma [4]
------------------------------------------------------------------------------------

References

1 FDA Approved Drug Products from FDA Official Website. 2022. Application Number: 761238.
2 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
3 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
4 FDA Drug Development and Drug Interactions